Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Biosimilars Offer New Hope for European Patients Facing High Eculizumab Costs

May 20th 2025

By Skylar Jeremias

Article

Eculizumab biosimilars could provide European patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome better access to care for a better price, similar to successes seen in other biosimilar markets, according to a review.

BioRationality: The Revised Indian Biosimilar Guidelines Finally Bring Rationality

May 19th 2025

By Sarfaraz K. Niazi, PhD

Article

The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High

May 17th 2025

By Skylar Jeremias

Article

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.

The Top 5 Biosimilar Articles for the Week of May 12

May 16th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of May 12, 2025.

Follow-On Biologics Poised to Expand Global Health Care Access and Lower Costs

May 15th 2025

By Cameron Santoro

Article

Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs and expanding treatment access.

Cimerli Offers a New, Interchangeable Biosimilar for Ocular Conditions

May 15th 2025

By Melissa Garcia, PharmD Candidate

Article

Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.

Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA

May 13th 2025

By Skylar Jeremias

Article

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.

Paving the Way for Equitable Biosimilar Access in Australian Dermatology Clinics

May 13th 2025

By Skylar Jeremias

Article

Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its health system—but a new report suggests biosimilars could offer financial relief, provided uptake barriers are addressed through policy reform and education.

Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs

May 10th 2025

By Deana Ferreri, PhD

Article

Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.

Eye on Pharma: Interchangeability, Private Labels, and Patent Settlements for Biosimilars

May 9th 2025

By Skylar Jeremias

Article